Imagine a disease where some people fight it off naturally while others get very sick, but doctors don't know why. This project is like building a massive library of patient data and biological samples to find the 'secret code' that explains these differences. By finding these markers, doctors can finally pick the right medicine for the right person instead of guessing.
Hepatitis D treatment is currently a 'one-size-fits-all' approach despite massive differences in how patients respond. This leads to wasted medical costs and poor patient outcomes because doctors cannot predict who will respond to specific antivirals.
A multicenter cohort of 750 patients and a centralized biobank containing plasma, serum, immune cells, and liver tissue.
If you are a drug developer dealing with low response rates to current HDV treatments — this project developed a multicenter cohort of 750 patients that identifies specific parameters to predict who will benefit from therapy. This allows for more precise patient selection in clinical trials.
If you are a biotech company dealing with the lack of biomarkers for liver disease progression — this project developed an unbiased screening of HDV-infected patients that identifies molecules determining infection outcomes. This can be turned into a diagnostic test for personalized surveillance.
If you are a clinic dealing with high costs of ineffective antiviral treatments — this project developed a personalized medicine approach that identifies which patients are likely to respond to bulevirtide or interferon. This reduces wasted spending on non-responsive patients.
Based on available project data, no specific pricing or cost for the resulting diagnostic tools is provided; the project focuses on research and cohort establishment.
The project uses a multicenter cohort of 750 patients across 5 countries, providing a scalable data foundation for future industrial diagnostic development.
Based on available project data, there are no specific details regarding patents or licensing agreements mentioned in the summary.
By identifying specific parameters that determine treatment success, the project provides the evidence needed for personalized treatment protocols in regulatory filings.
The project runs from 2022-10-01 to 2026-09-30, suggesting that validated markers may be available toward the end of 2026.
The consortium is purely academic and research-driven, consisting of 8 partners from 5 countries (DE, FR, IT, RO, SE). With 0% industry participation and 0 SMEs, the project is currently focused on fundamental discovery and clinical data collection rather than immediate commercialization.
Contact the Medizinische Hochschule Hannover for data access or collaboration on HDV biomarkers.
Contact us to bridge the gap between these clinical findings and your drug development pipeline.
